$BEAM
Beam Therapeutics Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023060683 Filed on November 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $316.2M $17.19M
YoY Change 1478.04% 8.82%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $43.26M $25.41M
YoY Change 90.72% 16.48%
% of Gross Profit
Research & Development $140.1M $100.1M
YoY Change 62.24% 17.31%
% of Gross Profit
Depreciation & Amortization $5.362M $5.187M
YoY Change 35.95% 49.35%
% of Gross Profit
Operating Expenses $183.3M $125.5M
YoY Change 68.16% 17.14%
Operating Profit -$108.3M
YoY Change 18.58%
Interest Expense $9.442M $6.180M
YoY Change -70.67% -41.22%
% of Operating Profit
Other Income/Expense, Net $1.863M $12.18M
YoY Change -90.42% 26.36%
Pretax Income $144.2M -$96.09M
YoY Change -485.99% 17.66%
Income Tax $1.366M $0.00
% Of Pretax Income 0.95%
Net Earnings $142.8M -$96.09M
YoY Change -472.36% -12.31%
Net Earnings / Revenue 45.16% -558.88%
Basic Earnings Per Share -$1.22
Diluted Earnings Per Share $1.77 -$1.22
COMMON SHARES
Basic Shares Outstanding 81.50M 79.20M
Diluted Shares Outstanding 79.02M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.190B $1.016B
YoY Change 10.36% -7.22%
Cash & Equivalents $435.9M $169.0M
Short-Term Investments $754.0M $846.4M
Other Short-Term Assets $21.17M $24.10M
YoY Change 43.39% 67.85%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.211B $1.040B
YoY Change 10.81% -6.26%
LONG-TERM ASSETS
Property, Plant & Equipment $125.0M $127.5M
YoY Change 8.08% 14.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change
Other Assets $2.146M $2.652M
YoY Change 11.13% 41.52%
Total Long-Term Assets $248.7M $251.0M
YoY Change -0.06% 4.0%
TOTAL ASSETS
Total Short-Term Assets $1.211B $1.040B
Total Long-Term Assets $248.7M $251.0M
Total Assets $1.460B $1.291B
YoY Change 8.79% -4.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.617M $3.177M
YoY Change -82.09% -54.77%
Accrued Expenses $124.0M $53.70M
YoY Change 112.12% 10.9%
Deferred Revenue $68.71M $153.5M
YoY Change -49.47% -4.01%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $484.0K $1.100M
YoY Change -73.88% -50.23%
Total Short-Term Liabilities $205.6M $220.4M
YoY Change -8.06% -7.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $300.0K
YoY Change -100.0% -78.39%
Other Long-Term Liabilities $298.0K $1.048M
YoY Change 33.04% 314.23%
Total Long-Term Liabilities $298.0K $1.048M
YoY Change 33.04% 314.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $205.6M $220.4M
Total Long-Term Liabilities $298.0K $1.048M
Total Liabilities $478.4M $511.6M
YoY Change -21.35% -19.53%
SHAREHOLDERS EQUITY
Retained Earnings -$1.200B -$1.300B
YoY Change 9.09% 30.0%
Common Stock $816.0K $794.0K
YoY Change 14.61% 12.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $981.3M $778.9M
YoY Change
Total Liabilities & Shareholders Equity $1.460B $1.291B
YoY Change 8.79% -4.42%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income $142.8M -$96.09M
YoY Change -472.36% -12.31%
Depreciation, Depletion And Amortization $5.362M $5.187M
YoY Change 35.95% 49.35%
Cash From Operating Activities $135.1M -$89.80M
YoY Change -295.22% 20.54%
INVESTING ACTIVITIES
Capital Expenditures $3.589M $7.900M
YoY Change -56.55% -167.02%
Acquisitions
YoY Change
Other Investing Activities $101.7M -$2.300M
YoY Change -16.44% -90.57%
Cash From Investing Activities $98.10M -$10.30M
YoY Change -13.52% -71.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 33.71M 36.70M
YoY Change 5.31% 2249.55%
NET CHANGE
Cash From Operating Activities 135.1M -89.80M
Cash From Investing Activities 98.10M -10.30M
Cash From Financing Activities 33.71M 36.70M
Net Change In Cash 266.9M -63.40M
YoY Change 249.97% -41.89%
FREE CASH FLOW
Cash From Operating Activities $135.1M -$89.80M
Capital Expenditures $3.589M $7.900M
Free Cash Flow $131.5M -$97.70M
YoY Change -269.76% 55.8%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001745999
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
CY2022Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39208
dei Entity Registrant Name
EntityRegistrantName
Beam Therapeutics Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-5238376
dei Entity Address Address Line1
EntityAddressAddressLine1
238 Main Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
327-8775
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
BEAM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
81504057
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
169049000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
232767000
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
846408000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
845367000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
24084000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14762000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
1039541000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1092896000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
127521000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
115620000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8680000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
12754000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
112140000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
118513000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2652000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1931000
CY2023Q3 us-gaap Assets
Assets
1290534000
CY2022Q4 us-gaap Assets
Assets
1341714000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3177000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9029000
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
41769000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
48059000
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
8900000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
18300000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
153484000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
135974000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11951000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
10380000
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1084000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1853000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
220365000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
223595000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
160637000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
168625000
CY2023Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
304000
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1154000
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
4586000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
12463000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
124653000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
202179000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1048000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
224000
CY2023Q3 us-gaap Liabilities
Liabilities
511593000
CY2022Q4 us-gaap Liabilities
Liabilities
608240000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
79382032
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79382032
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71277339
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71277339
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
794000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
712000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2112857000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1792554000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2024000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2430000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1332686000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1057362000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
778941000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
733474000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1290534000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1341714000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17193000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15799000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
61517000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
40883000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
100050000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
85287000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
297304000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
225253000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25410000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21815000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
73556000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
65124000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
125460000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
107102000
us-gaap Operating Expenses
OperatingExpenses
370860000
us-gaap Operating Expenses
OperatingExpenses
290377000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-108267000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-91303000
us-gaap Operating Income Loss
OperatingIncomeLoss
-309343000
us-gaap Operating Income Loss
OperatingIncomeLoss
-249494000
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
4700000
CY2022Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-4900000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
9400000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
20900000
CY2023Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-11221000
CY2022Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
10431000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-17870000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-1378000
CY2023Q3 beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-6002000
CY2022Q3 beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
875000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-7877000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
543000
CY2023Q3 beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
12698000
CY2022Q3 beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
4982000
beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
34612000
beam Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
7686000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12179000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9638000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
34019000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
26665000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-96088000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-81665000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-275324000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-222829000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2410000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2410000
CY2022Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-25500000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-25500000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-96088000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-109575000
us-gaap Net Income Loss
NetIncomeLoss
-275324000
us-gaap Net Income Loss
NetIncomeLoss
-250739000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-9000
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-484000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
406000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-4624000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-96097000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-110059000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-274918000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-255363000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.22
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.56
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.59
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79024647
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79024647
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70343196
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70343196
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75902612
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75902612
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69758434
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69758434
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
826738000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1412000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
53936000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18035000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
820000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2659000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-69214000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
829068000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
22300000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21578000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
646000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1481000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-71950000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
800161000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1664000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22209000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
502000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-484000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-109575000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
714477000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
733474000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1708000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
93810000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23917000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3392000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1665000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-96460000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
761506000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
107183000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26278000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
702000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1250000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-82776000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
811643000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1324000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34944000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25835000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1292000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-9000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-96088000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
778941000
us-gaap Profit Loss
ProfitLoss
-275324000
us-gaap Profit Loss
ProfitLoss
-250739000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-25500000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14650000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10203000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
22389000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
4308000
us-gaap Share Based Compensation
ShareBasedCompensation
76030000
us-gaap Share Based Compensation
ShareBasedCompensation
61822000
beam Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
7117000
beam Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
6237000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
9400000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
20900000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
-7877000
beam Change In Fair Value Of Contingent Consideration Liabilities
ChangeInFairValueOfContingentConsiderationLiabilities
543000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-17870000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-1378000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10043000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7192000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5810000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-527000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2738000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-25376000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-7161000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
13496000
beam Increase Decrease In Collaboration Receivable
IncreaseDecreaseInCollaborationReceivable
-300000000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-60016000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-15883000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
823000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2539000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-284268000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
91718000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
30143000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
40690000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
931066000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
1378609000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
934950000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
844524000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26259000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-574775000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
236568000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
76365000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3032000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3076000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
631000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
134000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1620000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1697000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5386000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1968000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
242735000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
79578000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-67792000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-403479000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
245521000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
572740000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
177729000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
169261000
us-gaap Interest Paid Net
InterestPaidNet
140000
us-gaap Interest Paid Net
InterestPaidNet
300000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2192000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
5658000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
744000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
35877000
beam Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
25500000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1300000000
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
1000000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, incremental borrowing rate used in the calculation of lease liabilities, research and development expenses, stock-based compensation, contingent consideration liabilities, success payments and certain judgments regarding revenue recognition. Actual results could differ from these estimates.</span></p>
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
169049000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
156511000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8680000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
12750000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
177729000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
169261000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
172341000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
145790000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
44820000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
30170000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
127521000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
115620000
CY2023Q3 us-gaap Depreciation
Depreciation
5187000
CY2022Q3 us-gaap Depreciation
Depreciation
3473000
us-gaap Depreciation
Depreciation
14650000
us-gaap Depreciation
Depreciation
10153000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
40.28
CY2023Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-11221000
CY2022Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
10431000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-17870000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-1378000
CY2023Q3 beam Available For Sale Debt Securities And Equity Securities Fv Ni Amortized Cost Basis
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis
848432000
CY2023Q3 beam Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Gain Before Taxes
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes
10000
CY2023Q3 beam Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Loss Before Taxes
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes
2034000
CY2023Q3 beam Available For Sale Debt Securities And Equity Securities Fv Ni
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi
846408000
CY2022Q4 beam Available For Sale Debt Securities And Equity Securities Fv Ni Amortized Cost Basis
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis
847797000
CY2022Q4 beam Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Gain Before Taxes
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes
85000
CY2022Q4 beam Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Loss Before Taxes
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes
2515000
CY2022Q4 beam Available For Sale Debt Securities And Equity Securities Fv Ni
AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi
845367000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13738000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19122000
CY2023Q3 beam Accrued Research Costs
AccruedResearchCosts
11657000
CY2022Q4 beam Accrued Research Costs
AccruedResearchCosts
4844000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
7122000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6751000
CY2023Q3 beam Accrued Process Development And Manufacturing Costs
AccruedProcessDevelopmentAndManufacturingCosts
4475000
CY2022Q4 beam Accrued Process Development And Manufacturing Costs
AccruedProcessDevelopmentAndManufacturingCosts
5080000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4777000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
12262000
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
41769000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
48059000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25835000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22209000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
76030000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
61822000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7548392
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
41.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2245392
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
604706
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.9
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
461827
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
61.93
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8727251
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
42.59
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4684704
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
35.6
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
28.21
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10905069
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9254842
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-96088000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-109575000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-275324000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-250739000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79024647
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79024647
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70343196
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70343196
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75902612
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75902612
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69758434
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69758434
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.22
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.56
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.59
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2400000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2400000
beam Number Of Founder Shareholders
NumberOfFounderShareholders
3

Files In Submission

Name View Source Status
0000950170-23-060683-index-headers.html Edgar Link pending
0000950170-23-060683-index.html Edgar Link pending
0000950170-23-060683.txt Edgar Link pending
0000950170-23-060683-xbrl.zip Edgar Link pending
beam-20230930.htm Edgar Link pending
beam-20230930.xsd Edgar Link pending
beam-ex31_1.htm Edgar Link pending
beam-ex31_2.htm Edgar Link pending
beam-ex32_1.htm Edgar Link pending
beam-20230930_def.xml Edgar Link unprocessable
beam-20230930_lab.xml Edgar Link unprocessable
beam-20230930_pre.xml Edgar Link unprocessable
beam-20230930_cal.xml Edgar Link unprocessable
beam-20230930_htm.xml Edgar Link completed
beam-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable